ArticleInfection & chemotherapy2024
Antimicrobial Resistance of
Article in Infection & chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 7 citations in OpenAlex.
- The impact of pneumococcal conjugate vaccines on disease epidemiology, serotype distribution, and antimicrobial resistance in children. A 25-year observational study in Athens, Greece (1996-2021).Human vaccines & immunotherapeutics · 2026Observational
- Lineage structure and penicillin-binding protein variability in clinicalFrontiers in public health · 2026Article
- Impact of sequential pediatric pneumococcal conjugate vaccination (PCV10/PCV13/PCV10) on serotype distribution and antimicrobial resistance in invasive and non-invasiveFrontiers in microbiology · 2026Article
- Global Antimicrobial Non-Susceptibility Patterns ofInfection and drug resistance · 2026Review
- Article
- Molecular Epidemiology, Antimicrobial Resistance, and Clinical Characteristics ofAntibiotics (Basel, Switzerland) · 2025Article
- Molecular characterization and antimicrobial resistance ofIJID regions · 2025Article
- Genomic analysis and pneumococcal population dynamics across PCV implementation in South Korea, 1997-2023.Microbial genomics · 2025Article
- Bactofencin YH, a novel bacteriocin with high inhibitory activity against clinical Streptococcus species.World journal of microbiology & biotechnology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPneumococcal disease is still considered a global problem. With the introduction of pneumococcal conjugate vaccines (PCVs) serotype epidemiology changed, but antimicrobial resistance persists constituting a serious problem. The current study aimed to determine the serotype distribution and the antimicrobial susceptibility of recent MATERIALS AND
methodsFrom January 2017 to December 2022 we evaluated 116 nonduplicate
resultsAmong the 116 isolates, 31% were recognized as invasive pneumococcal strains, while 69% were non-invasive. The isolates tested belonged to 25 different serotypes. The most prevalent serotypes were 11A (10.3%), and 35B (10.3%), followed by 3 (9.5%), 15A (7.8%), 25F (6.9%), 19A (5.3%), 35F (5.3%), and others (44.6%). The coverage rates of PCV13 and the pneumococcal polysaccharide vaccine (PPSV23) were 26.7% and 57.8%, respectively. PCV13 and PPSV23 serotypes decreased between 2017 - 2019 and 2020 - 2022, with a parallel increase in the non-vaccine types. Resistance rates to erythromycin, clindamycin, trimethoprim/sulfamethoxazole, penicillin, levofloxacin, and ceftriaxone, were 40.5%, 21.6%, 13.8%, 12.1%, 3.4%, and 0%, respectively. All isolates were susceptible to vancomycin, linezolid, and daptomycin. MDR was observed among 36 (31%)
conclusionThe increasing levels of resistance in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.